Citius Oncology, Inc. (CTOR) vs PDS Biotechnology Corporation (PDSB)

A side-by-side comparison of Citius Oncology, Inc. and PDS Biotechnology Corporation across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

CTOR

Citius Oncology, Inc.

$77M

$0.83HealthcareDelayed quote: Oct 6, 2026, 3:34 PM EDT

PDSB

PDS Biotechnology Corporation

$58M

$1.04HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT

Total return — CTOR vs PDSB

growth of $100 · dividends reinvested · last 2y

CTOR -92.4% (-72.4%/yr)PDSB -69.0% (-44.3%/yr)PDSB compounded faster over this window

CTOR PDSB

CTOR vs PDSB: by the numbers

•CTOR is the larger company ($77M vs $58M market cap).
•Both run net losses; PDSB's is the smaller (0.00% vs -648.32% net margin).

Metrics side by side

Valuation

Metric	CTOR	PDSB
Forward P/E	8.31	N/A
P/S ratio	10.88	N/A
P/B ratio	1.91	N/A

Profitability

Metric	CTOR	PDSB
Gross margin	0.00%	0.00%
Operating margin	0.00%	0.00%
Net margin	-648.32%	0.00%
ROE	-114.06%	N/A
ROIC	-88.72%	-3699.99%

Growth (annualized)

Metric	CTOR	PDSB
Total return CAGR (5Y)	N/A	-39.13%

Go deeper

Full CTOR analysis Full PDSB analysis Interactive comparison tool

Dig into the metrics

Citius Oncology ROE PDS Biotechnology ROE Citius Oncology operating margin PDS Biotechnology operating margin Citius Oncology revenue growth PDS Biotechnology revenue growth Citius Oncology free cash flow PDS Biotechnology free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.